Revvity, Inc. Common Stock (RVTY)

Check out the companies making headlines yesterday: Regal Rexnord (NYSE:RRX): Industrials products and automation company Regal Rexnord (NYSE:RRX) rose by 10...

Revvity (NYSE:RVTY) reported third-quarter results that exceeded its expectations, supported by stronger demand in its Life Sciences segment, continued growth in Diagnostics and expanding interest in artificial intelligence-related research tools. President and Chief Executive Officer Prahlad Singh

Life sciences company Revvity (NYSE:RVTY) reported revenue ahead of Wall Street’s expectations in Q3 2026, with sales up 7.4% year on year to $709.6 million....

Life Sciences surged 9% as AI demand expands across screening and detection.

What happened? Shares of life sciences company Revvity (NYSE:RVTY) jumped 12.2% in the morning session after the company reported third-quarter 2026 financia...

Life sciences company Revvity (NYSE:RVTY) beat Wall Street’s revenue expectations in Q3 2026, with revenue rising 10.3% year on year to $728.9 million. The c...

Life sciences company Revvity (NYSE:RVTY) will be reporting earnings this Tuesday before the bell. Here’s what you need to know. Revvity beat analysts’ reven...

The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant ch...

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it eff...

The stocks featured in this article have all approached their 52-week highs. When these price levels hit, it typically signals strong business execution, pos...

Revvity has been on fire lately. In the past six months alone, the company’s stock price has rocketed 78%, reaching $150.93 per share. This was partly due to...

Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cord...

Great things are happening to the stocks in this article. They’re all outperforming the market over the last month because of positive catalysts such as a ne...

As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the research tools & consumables industry,...

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advanceme...